Canadianbusiness.com
05/17/2010
Simcere Pharmaceutical Group said Monday it is being fined 25.6 million yuan ($3.7 million) by Chinese authorities due to the production of substandard rabies vaccines.
The company, based in China, said Changzhou Food and Drug Administration imposed the fine on its Jiangsu Yanshen Biological Technology Stock Co. Ltd. unit.
Jiangsu Yanshen also will bear the cost of patient revaccinations up to 23 million yuan ($3.4 million). Also, members of Jiangsu Yanshen’s management team and employees directly involved in the production of the substandard vaccines will be prohibited from making or marketing pharmaceutical products for 10 years.
There is also a criminal investigation under way, the company said.